SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

Roche Wins First U.S. Approval for Breast Cancer Drug Wilserdly

Roche Holding won its first U.S. approval for Wilserdly. Vontobel analyst Stefan Schneider said the drug could become a major oncology treatment and strengthen Roche’s growth outlook in breast cancer.

RO

Story updates

09:31:22 AM UTC
SquawkNews
Roche Holding got U.S. approval for its new drug Wilserdly in advanced breast cancer four weeks ahead of schedule, but the medicine's label includes warnings and precautions that weren't expected, RBC Capital Markets analysts say in a research note. The Swiss drugmaker is awaiting approval for Wils…

Roche Holding won its first U.S. approval for breast-cancer drug Wilserdly, which has the potential to become a new major oncology drug for the Swiss pharmaceutical company, Vontobel's Stefan Schneider says in a note. "The approval strengthens Roche's growth outlook in breast cancer and could be fo…

Related stories